NPM1突变定义强化化疗预后良好的MDS及MDS/MPN亚组
该回顾性研究纳入31例伴NPM1突变的MDS或MDS/MPN患者,中位年龄62岁,24例(77%)核型正常。接受强化化疗者完全缓解率90%对28%(P=.004),中位无进展生存期未达到对7.5个月(P=.023),总生存期未达到对16个月(P=.047)。
要点
- 伴NPM1突变的MDS/MDS/MPN多为正常核型且伴多系发育异常。
- 强化化疗者完全缓解率90%对28%,无进展生存与总生存均优于其他治疗。
- 强化化疗和异基因造血干细胞移植可能改善适合该类治疗患者的结局。
核心结论
- NPM1突变可定义一类接受强化化疗后结局良好的MDS或MDS/MPN患者亚组。
- 强化化疗和异基因造血干细胞移植可能改善适合此类治疗患者的临床结局。
研究设计与样本
- 回顾性评估31例伴NPM1突变的MDS或MDS/MPN患者的临床病理特征及治疗影响。
- 22例患者在诊断时接受二代测序。
- 中位年龄62岁(范围19-86岁),24例(77%)核型正常,全部有多系发育异常。
主要发现
- 19/31例(61%)可归为伴原始细胞增多的MDS。
- NPM1突变中位等位基因频率0.38(范围0.09-0.49),突变负荷与骨髓原始细胞比例不相关。
- 31例中10例(32%)接受细胞毒化疗,20例(65%)接受去甲基化药物,1例(4%)接受来那度胺。
- 16例(52%)有连续测序,突变负荷与疾病状态及治疗反应相关。
- 化疗者完全缓解率90%对28%(P=.004),中位无进展生存期未达到对7.5个月(P=.023),总生存期未达到对16个月(P=.047)。
关键数值与推荐
- 完全缓解率:化疗组90%对非化疗组28%(P=.004)。
- 中位无进展生存期:化疗组未达到对非化疗组7.5个月(P=.023)。
- 中位总生存期:化疗组未达到对非化疗组16个月(P=.047)。
临床怎么用
- 作者认为,对适合强化化疗的NPM1突变MDS或MDS/MPN患者,强化化疗和异基因造血干细胞移植可能与临床结局改善相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nucleophosmin (NPM1) mutations are common in acute myeloid leukemia and are associated with high remission rates and prolonged survival with intensive chemotherapy. NPM1 mutations are rare in myelodysplastic syndromes (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN), and the clinical outcomes of these patients, when treated with intensive chemotherapy, are unknown. We retrospectively evaluated the clinicopathologic characteristics and the impact of therapy in 31 patients with MDS or MDS/MPN and NPM1 mutations. Next-generation sequencing was performed at diagnosis in 22 patients. Median age was 62 years (range, 19-86). Twenty-four patients (77%) had normal karyotype, and all had multilineage dysplasia. Most patients could be classified as MDS with excess blasts (19/31, 61%). NPM1 mutations were detected at a median allele frequency of 0.38 (range, 0.09-0.49). Mutation burden did not correlate with bone marrow blast frequency, and its clearance seemed to be associated with decreased morphologic dysplasia. Ten of the 31 patients (32%) received cytotoxic chemotherapy, 20 (65%) hypomethylating agents, and 1 (4%) lenalidomide. Sequential sequencing was available in 16 (52%) patients, and mutation burden correlated with disease status and response to therapy. Patients treated with chemotherapy had higher complete response rates (90% vs 28%, P = .004), longer median progression-free survival (not reached vs 7.5 months, P = .023), and overall survival (not reached vs 16 months, P = .047). Intensive chemotherapy and allogeneic stem cell transplantation (SCT) may be associated with improved clinical outcomes in patients with NPM1-mutated MDS or MDS/MPN who are candidates for this form of therapy.
引用
- Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, et al. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019. PMID: 30902805. doi:10.1182/bloodadvances.2018026989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。